New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2) | Zendy

Hannele YkiJärvinen | Zendy; Richard M. Bergenstal | Zendy; M. Ziemen | Zendy; Marek Wardęcki | Zendy; Isabel Muehlen-Bartmer | Zendy; Emmanuelle Boëlle | Zendy; Matthew C. Riddle | Zendy

Open Access

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Author(s) -

Hannele YkiJärvinen,

Richard M. Bergenstal,

M. Ziemen,

Marek Wardęcki,

Isabel Muehlen-Bartmer,

Emmanuelle Boëlle,

Matthew C. Riddle

Publication year - 2014

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-0990

Subject(s) - medicine , insulin glargine , glycemic , hypoglycemia , basal (medicine) , diabetes mellitus , type 2 diabetes , insulin , endocrinology , randomized controlled trial , clinical endpoint , gastroenterology

To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes using basal insulin (≥42 units/day) plus oral antihyperglycemic drugs (OADs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research